Clinical trials
Neuroendocrine Carcinomas (NEC) clinical trials
Below are recruiting neuroendocrine carcinomas (nec) clinical trials, each written for real people, not researchers. We’re tracking 24 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07509034RecruitingPhase 1
Targeted immune cells for recurrent small cell lung cancer
This trial tests a special immune cell therapy (CAR T cells) that targets a protein called B7-H3 on your cancer cells. It is for people with small cell lung cancer or similar neuroendocrine cancers that have returned or not responded to standard treatments.
Bethesda, MarylandAges 18–120 - NCT07518602RecruitingPhase 2
Chidamide, Sintilimab, and Bevacizumab for Advanced Neuroendocrine Cancer
This trial tests a combination of three drugs—chidamide (a protein regulator), sintilimab (an immune-boosting antibody), and bevacizumab (a growth-blocking antibody)—for patients with advanced neuroendocrine cancer that has spread or cannot be removed surgically and has progressed despite an initial treatment. The goal is to see if this combination can shrink tumors and help patients live longer.
Guangzhou, GuangdongAges 18–75 - NCT07488923RecruitingPhase 1
ML261 CAR T therapy for advanced small cell lung cancer and related neuroendocrine cancers
This trial tests a new treatment called ML261, which uses your own immune cells (T cells) that have been modified to target DLL3, a protein found on certain cancer cells. It is for people with advanced small cell lung cancer or other neuroendocrine cancers that have not responded to standard treatments.
St Louis, MissouriAges 18 years+ - NCT07429851Recruiting
Comparing thymus, lung, and pancreas neuroendocrine tumors
This trial is studying well-differentiated high-grade neuroendocrine tumors that start in the thymus, lung, or pancreas. It compares these tumors to understand them better and find better treatments.
Milan, ItalyAges Any age - NCT07278479RecruitingPhase 1/Phase 2
Study of a targeted radiation therapy for small cell lung cancer
This trial tests a new drug called MP0712 that delivers radiation directly to cancer cells that have a marker called DLL3. It is for people with small cell lung cancer or other solid tumors that express DLL3, whose cancer has come back after prior treatments.
Tampa, FloridaAges 18 years+ - NCT07192991Recruiting
Neuroendocrine Cancers: Patient Journey and Treatment in Latin America
This study looks at how people with certain neuroendocrine cancers (including small cell lung cancer and large-cell neuroendocrine carcinoma) are diagnosed and treated in Latin America. It aims to understand the patient journey and improve future care.
Buenos Aires, Buenos AiresAges 18 years+ - NCT07080242RecruitingPhase 1
Study of BL-M14D1 for small cell lung cancer and neuroendocrine tumors
This trial tests an investigational drug, BL-M14D1, for people with certain types of neuroendocrine tumors or small cell lung cancer that have progressed after standard treatment. The drug targets a protein called DLL3 found on these cancer cells, which may help shrink tumors or slow their growth.
Huntsville, AlabamaAges 18 years+ - NCT07006727RecruitingPhase 1
Study of a new drug for advanced DLL3-positive solid tumors
This trial tests an experimental treatment for several types of advanced cancer that have stopped responding to standard therapy. The drug targets a protein called DLL3 found on some tumor cells, which may help slow or stop tumor growth.
Iowa City, IowaAges 18–100 - NCT06943521RecruitingPhase 1/Phase 2
Study of MT-4561 for advanced solid tumors
This trial tests a new drug called MT-4561 in people with advanced solid tumors that have not responded to prior treatments. It aims to see if the drug can help shrink tumors or slow their growth.
Los Angeles, CaliforniaAges 18 years+ - NCT06937905RecruitingPhase 3
Tarlatamab vs chemo for advanced NEC after one prior treatment
This trial tests a new immunotherapy drug called tarlatamab, which targets the DLL3 protein on cancer cells, versus standard chemotherapy for people with advanced neuroendocrine carcinoma (NEC). You may qualify if your NEC has gotten worse after just one prior platinum chemotherapy and your tumor has DLL3.
AngersAges 18 years+ - NCT06893783RecruitingPhase 2
Tarlatamab for advanced extrapulmonary neuroendocrine carcinoma
This study tests a drug called tarlatamab for people with a rare cancer called extrapulmonary neuroendocrine carcinoma that has grown or returned after standard chemotherapy. The goal is to see if tarlatamab can help shrink tumors and improve outcomes.
SeoulAges 19 years+ - NCT06889493RecruitingPhase 1
SVV-001 plus immunotherapy for neuroendocrine cancers
This trial tests a new virus-based treatment (SVV-001) combined with two immunotherapy drugs (nivolumab and ipilimumab) for people with advanced neuroendocrine cancers that have gotten worse after at least one prior treatment. The goal is to see if this combination can help shrink tumors or slow the cancer's growth.
Miami, FloridaAges 18 years+ - NCT04268121RecruitingPhase 2
Neoadjuvant chemotherapy before surgery for certain digestive neuroendocrine cancers
This study looks at whether chemotherapy given before surgery improves how long patients live without the cancer coming back. It’s aimed at people with localized, poorly differentiated digestive neuroendocrine carcinoma with a higher growth rate marker.
AmiensAges 18 years+ - NCT05652686RecruitingPhase 1/Phase 2
Studying PT217 for neuroendocrine cancers
This trial tests a new drug called Peluntamig (PT217) for people with certain types of neuroendocrine cancers, like small cell lung cancer. It aims to see if the drug can help when standard treatments stop working or aren't an option.
Duarte, CaliforniaAges 18 years+ - NCT05058651RecruitingPhase 2/Phase 3
Atezolizumab plus chemo for advanced neuroendocrine cancer outside the lung
This trial tests whether adding an immunotherapy drug called atezolizumab to standard chemotherapy helps people with advanced neuroendocrine carcinoma (a rare and aggressive cancer) that started outside the lung. The goal is to see if the combination works better than chemo alone.
Anchorage, AlaskaAges 18 years+ - NCT04723095Recruiting
Cervical neuroendocrine cancer registry for past and present patients
This study builds a registry (a secure database) of people who have had cervical neuroendocrine cancer, including small cell or large cell types. It helps researchers learn more about these cancers and may improve future care and research planning.
Houston, TexasAges Any age - NCT06070740RecruitingPhase 2
Durvalumab Plus Chemo for Advanced Gastrointestinal NEC
This trial tests a combination of durvalumab (an immunotherapy drug) plus a chemotherapy called XELOX as the first treatment for advanced gastrointestinal neuroendocrine carcinoma (NEC). It aims to see if the combination works better than chemo alone.
Beijing, Beijing MunicipalityAges 18–75 - NCT07016230RecruitingPhase 2
Study of tarlatamab for small-cell lung cancer and other neuroendocrine cancers
This trial tests a new drug, tarlatamab, which targets a protein called DLL3 found on the surface of certain cancer cells. The goal is to see if it can shrink or control tumors in people with small-cell lung cancer or other poorly differentiated neuroendocrine cancers, and to learn more about who benefits most.
BordeauxAges 18 years+ - NCT05978284RecruitingPhase 1/Phase 2
Study of ZG006 for small cell lung cancer or neuroendocrine carcinoma
This trial tests a new drug, ZG006, that targets a protein called DLL3 found on some cancer cells. It may be an option for people with small cell lung cancer or neuroendocrine carcinoma who have run out of standard treatments.
Zhengzhou, HenanAges 18–75 - NCT06393816RecruitingPhase 2
Durvalumab plus chemotherapy for advanced LCNEC lung cancer
This trial tests a combination of the immunotherapy drug durvalumab (Imfinzi) with standard chemotherapy (etoposide and a platinum drug) as a first treatment for advanced large-cell neuroendocrine carcinoma of the lung. The goal is to see if this combination works better than chemotherapy alone.
Aix-en-ProvenceAges 18 years+ - NCT07174583RecruitingPhase 1/Phase 2
Study of IDE849 for DLL3-positive cancers like SCLC
This trial tests a new drug called IDE849 for cancers that make a protein called DLL3, including small cell lung cancer and some neuroendocrine tumors. It is for people whose cancer has progressed after standard treatments, and may be given alone or combined with other drugs like durvalumab or IDE161.
Denver, ColoradoAges 18 years+ - NCT05165407RecruitingPhase 2
Study drugs for advanced high-grade neuroendocrine tumors
This trial tests whether adding three medicines—sintilimab, IBI310, and surufatinib—can control advanced, high-grade neuroendocrine tumors (that cannot be removed by surgery or have spread). It may help if your cancer has grown despite standard treatment, or if you cannot take standard treatment due to side effects.
Beijing, Beijing MunicipalityAges 18–75 - NCT06503146RecruitingPhase 2
New imaging tracer for detecting various cancers
This trial tests a new imaging agent, [18F]FAPI-74, which might help detect certain cancers more clearly. The scan looks for a protein called fibroblast activation protein (FAP) that is often found in tumors. If you have one of the listed cancers and are about to start treatment, this study could help doctors see where the cancer is and how it responds to therapy.
Bethesda, MarylandAges 18–120 - NCT07544654RecruitingPhase 3
Study comparing obrixtamig plus chemotherapy for advanced neuroendocrine cancer
This trial tests a new drug called obrixtamig combined with standard chemotherapy for advanced neuroendocrine cancer (a rare type of cancer). You'd receive one cycle of standard chemotherapy first, then be randomly assigned to either continue with the new drug plus chemotherapy or standard chemotherapy alone.
Scottsdale, ArizonaAges 18 years+
Hear when a new Neuroendocrine Carcinomas (NEC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for neuroendocrine carcinomas (nec)?
- Yes. Clin2 currently lists 24 recruiting neuroendocrine carcinomas (nec) studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a neuroendocrine carcinomas (nec) trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a neuroendocrine carcinomas (nec) trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.